Safety of subretinal delivery of RGX-314 (AAV8-anti-VEGF Fab) in the non-human primate as assessed by full-field ERG
Arkady Lyubarsky(Penn Presbyterian Medical Center), Jean Bennett(Penn Presbyterian Medical Center), James M. Wilson(St Bartholomew's Hospital), Erin Bote(University of Pennsylvania), Erik Wielechowski(University of Pennsylvania), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Albert M. Maguire(Children's Hospital of Philadelphia), Jessica Ijams Wolfing Morgan(Penn Presbyterian Medical Center), Tomás S. Alemán(Children's Hospital of Philadelphia), Anna Tretiakova(Pfizer (United States)), Leah Makaron(University of Pennsylvania)
Investigative Ophthalmology & Visual Science
July 13, 2018
Cited by 1
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703